Association of Serum Interleukin-6 and Interleukin-8 Levels with Clinical Benefit from Immune Checkpoint Inhibitors in Patients with Advanced Gastric Cancer
Yuan Yuan1, Liang Han1, Yu Feng1, Xiaowu Li11Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou, China,
Objectives: This study mainly analyzes the association between serum interleukin-6(IL-6) and interleukin-8(IL-8) levels and clinical benefit from immune checkpoint inhibitors in patients with advanced gastric cancer. Methods: The clinical characteristics of 51 patients with advanced gastric cancer, diagnosed in our hospital and treated with immune checkpoint inhibitors, were analyzed retrospectively in our study. Results: After three cycles of immunotherapy, the level of serum IL-6 decreased in 10 patients (37%) and the level of serum IL-8 decreased in 27 patients (52%). Compared with patients with increased serum IL-6 level, patients with decreased serum IL-6 level tended to have higher partial response (PR), stable disease (SD), but the difference was not statistically significant. Compared with patients with increased serum IL-8 level, there were significant differences in PR, SD for patients with decreased serum IL-8 level(P?0.05). Patients with decreased serum IL-6 or IL-8 levels tended to have better progression-free survival(PFS) and overall survival(OS) than those with increased serum IL-6 or IL-8 levels. Conclusion: The changes in IL-6 and IL-8 levels could be as predictive indicators to predict benefit from immune checkpoint inhibition in advanced gastric cancer. Patients with decreased serum IL-6 or IL-8 levels during immunotherapy may achieve better clinical benefit. Keywords: Gastric cancer, interleukin-6, interleukin-8, immune checkpoint inhibitor
Cite This Article
Yuan Y, Han L, Feng Y, Li X. Association of Serum Interleukin-6 and Interleukin-8 Levels with Clinical Benefit from Immune Checkpoint Inhibitors in Patients with Advanced Gastric Cancer. EJMO. 2023; 7(3): 227-231
Corresponding Author: Xiaowu Li